<DOC>
	<DOC>NCT00334425</DOC>
	<brief_summary>To evaluate the effect of LH-activity supplementation during the early follicular phase in GnRHa down-regulated women undergoing IVF in terms of S-Estradiol levels on hCG day by comparing different combinations with HP-HMG and r-FSH.</brief_summary>
	<brief_title>The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Females between the ages of 18 38 years (both included) at the time of randomisation Patients for whom treatment with gonadotrophins and GnRH agonist (long protocol) in IVF setting is considered appropriate according to the criteria of the participating centre Infertility for at least 1 year before randomisation (except for tubal infertility) A maximum of two previous consecutive unsuccessful IVF cycles (i.e. not resulting in an ongoing pregnancy 25 34 days of menstruation cycle Body mass index (BMI) &lt; 29 kg/m2 Any clinically significant systemic disease (e.g., insulin dependent diabetes) Endocrine or metabolic abnormalities (pituitary, adrenal, thyroid, pancreas, liver, or kidney) which can compromise participation in the study Any concomitant medications that would interfere with evaluation of study medications. Specifically, any nonstudy hormonal therapy (except for thyroid medication), prostaglandin inhibitors (NSAIDs, including aspirin) and psychotropic agents (phenothiazine’s, major tranquillisers) at the time of study entry. Note: these medications are disallowed for the study duration. Presence of clinically significant uterine fibroids Undiagnosed vaginal bleeding Tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus Pregnancy, lactation or contraindication to pregnancy – must be confirmed by negative urinary pregnancy test at randomisation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>June 2006</verification_date>
</DOC>